Medical condition
Drug Development
Drug Development is a medical condition tracked by NovaPharmaNews. Browse the latest pharmaceutical industry coverage and developments.
Latest Drug Development news
China’s Rise in Drug Development Looms Over U.S. Oncology Market
Structured plan for China’s Rise in Drug Development Looms Over U.S. Oncology Market
FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development
The FDA has issued final guidance to assist sponsors in developing new antibacterial drugs for pulmonary tuberculosis. This guidance finalizes a draft released in December 2022 and aims to streamline the approval process for novel TB treatments.
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
Cardiovascular drug developer Kardigan is gearing up for an IPO on the Nasdaq Global Market to finance the late-stage development of its pipeline, including danicamtiv for genetic dilated cardiomyopathy. This move signals a potential uptick in biotech IPOs as the market becomes more discerning.
Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide
The FDA has released a guide aimed at accelerating drug development through the use of AI in clinical trials. This article outlines key takeaways and implications for pharmaceutical teams.
Can a Chaotic FDA Still Deliver on Faster Drug Development?
This article examines the FDA's chaotic environment and its impact on drug development timelines. We analyze the implications for pharmaceutical teams navigating these changes.
Hepatitis B Drug Developments and Lilly's Obesity Drug Returns
This article discusses the latest advancements in hepatitis B drug development and the implications of CVS reinstating Lilly's obesity drug on formularies.
SGS Acquires Keystone Bioanalytical: A Game Changer for Drug Development
SGS has acquired Keystone Bioanalytical, significantly enhancing its drug development lifecycle testing capabilities. This strategic move is poised to impact the North American pharma and biotech industries.
AI Drug Development: Insights from a Biotech CEO
This article delves into the insights shared by a biotech CEO regarding the realities of AI in drug development, addressing common misconceptions and implications for the industry.